Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Marmé D[au]:

Tumor Angiogenesis: A Key Target for Cancer Therapy. Marmé D et al. Oncol Res Treat. (2018)

Advances in Cancer Therapy: Immunotherapies. Marmé D et al. Oncol Res Treat. (2016)

Advances in Cancer Therapy: Targeted Therapies. Marmé D et al. Oncol Res Treat. (2016)

Search results

Items: 1 to 50 of 142

1.

Tumor Angiogenesis: A Key Target for Cancer Therapy.

Marmé D.

Oncol Res Treat. 2018;41(4):164. doi: 10.1159/000488340. Epub 2018 Mar 28. No abstract available.

2.

Advances in Cancer Therapy: Liquid Biopsy.

Marmé D.

Oncol Res Treat. 2017;40(7-8):402-403. doi: 10.1159/000479186. Epub 2017 Jul 19. No abstract available.

3.

Advances in Cancer Therapy: Targeted Therapies.

Marmé D.

Oncol Res Treat. 2016;39(12):758-759. Epub 2016 Nov 24. No abstract available.

4.

Advances in Cancer Therapy: Immunotherapies.

Marmé D.

Oncol Res Treat. 2016;39(6):324-5. doi: 10.1159/000446635. Epub 2016 May 25. No abstract available.

5.

Personalized cancer medicine.

Marmé D, Hallek M.

Onkologie. 2012;35 Suppl 1:2. doi: 10.1159/000335980. Epub 2012 Jan 20. No abstract available.

PMID:
22286580
6.

Differential gene expression in response to ventricular unloading in rat and human myocardium.

Doenst T, Bugger H, Leippert S, Barleon B, Marme D, Beyersdorf F.

Thorac Cardiovasc Surg. 2006 Sep;54(6):381-7.

PMID:
16967373
7.

Targeting vascular endothelial growth factor pathway offers new possibilities to counteract microvascular disturbances during ischemia/reperfusion of the pancreas.

von Dobschuetz E, Meyer S, Thorn D, Marme D, Hopt UT, Thomusch O.

Transplantation. 2006 Aug 27;82(4):543-9.

PMID:
16926599
8.

Subtractive hybridization for differential gene expression in mechanically unloaded rat heart.

Bugger H, Leippert S, Blum D, Kahle P, Barleon B, Marme D, Doenst T.

Am J Physiol Heart Circ Physiol. 2006 Dec;291(6):H2714-22. Epub 2006 Jun 9.

9.

Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors.

Peifer C, Stoiber T, Unger E, Totzke F, Schächtele C, Marmé D, Brenk R, Klebe G, Schollmeyer D, Dannhardt G.

J Med Chem. 2006 Feb 23;49(4):1271-81.

PMID:
16480264
10.

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.

Mross K, Drevs J, Müller M, Medinger M, Marmé D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY, Günther C, Laurent D, Unger C.

Eur J Cancer. 2005 Jun;41(9):1291-9.

PMID:
15939265
11.

A single local injection of recombinant VEGF receptor 2 but not of Tie2 inhibits retinal neovascularization in the mouse.

Agostini H, Boden K, Unsöld A, Martin G, Hansen L, Fiedler U, Esser N, Marmé D.

Curr Eye Res. 2005 Apr;30(4):249-57.

PMID:
15823917
12.

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.

Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan M, Marmé D.

Ann Oncol. 2005 Apr;16(4):558-65. Epub 2005 Feb 10.

13.

Differentiation and definition of vascular-targeted therapies.

Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marmé D, Lorusso PM.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):416-20. Review.

14.

Changes in serum soluble VEGFR-1 and Tie-2 receptors in colorectal cancer patients following surgical resections.

Chin KF, Greenman J, Reusch P, Gardiner E, Marme D, Monson J.

Anticancer Res. 2004 Jul-Aug;24(4):2353-7.

15.
16.

Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements.

Hegen A, Koidl S, Weindel K, Marmé D, Augustin HG, Fiedler U.

Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1803-9. Epub 2004 Jul 29.

PMID:
15284088
17.

Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.

Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, Marmé D, Unger C.

Anticancer Res. 2004 May-Jun;24(3a):1759-63.

18.

Inhibition of tumor growth and angiogenesis by soluble EphB4.

Martiny-Baron G, Korff T, Schaffner F, Esser N, Eggstein S, Marmé D, Augustin HG.

Neoplasia. 2004 May-Jun;6(3):248-57.

19.

Protein kinase inhibitors: novel tools in cancer therapy.

Marmé D.

Urologe A. 2004 Sep;43 Suppl 3:S148. No abstract available.

PMID:
15148578
20.

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.

Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marmé D, Steward WP.

J Clin Oncol. 2003 Nov 1;21(21):3955-64. Epub 2003 Sep 29.

PMID:
14517187
21.

The impact of anti-angiogenic agents on cancer therapy.

Marmé D.

J Cancer Res Clin Oncol. 2003 Nov;129(11):607-20. Epub 2003 Sep 16. Review. No abstract available.

PMID:
13680378
22.

Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer: associations with disease recurrence.

Chin KF, Greenman J, Reusch P, Gardiner E, Marme D, Monson JR.

Eur J Surg Oncol. 2003 Aug;29(6):497-505.

PMID:
12875855
23.

VEGFs, angiopoietins, Ephrins and their receptors: putative targets for tumor therapy?

Marmé D.

Ann Hematol. 2002;81 Suppl 2:S66. No abstract available.

PMID:
12611080
24.

Implications of vascular endothelial growth factor, sFlt-1, and sTie-2 in plasma, serum and cerebrospinal fluid during cerebral ischemia in man.

Scheufler KM, Drevs J, van Velthoven V, Reusch P, Klisch J, Augustin HG, Zentner J, Marme D.

J Cereb Blood Flow Metab. 2003 Jan;23(1):99-110.

PMID:
12500095
25.

Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up?

Heilmann CA, Attmann T, von Samson P, Göbel H, Marmé D, Beyersdorf F, Lutter G.

Eur J Cardiothorac Surg. 2003 Jan;23(1):74-80.

PMID:
12493508
26.

Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats.

Fiedler U, Krissl T, Koidl S, Weiss C, Koblizek T, Deutsch U, Martiny-Baron G, Marmé D, Augustin HG.

J Biol Chem. 2003 Jan 17;278(3):1721-7. Epub 2002 Nov 9.

27.

Molecular mechanisms of anti-angiogenic effect of curcumin.

Gururaj AE, Belakavadi M, Venkatesh DA, Marmé D, Salimath BP.

Biochem Biophys Res Commun. 2002 Oct 4;297(4):934-42.

PMID:
12359244
28.

Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma.

Homer JJ, Greenman J, Drevs J, Marme D, Stafford ND.

Head Neck. 2002 Aug;24(8):773-8.

PMID:
12203803
29.

PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.

Drevs J, Müller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, Konerding MA, Allegrini PR, Wood J, Hennig J, Unger C, Marmé D.

Cancer Res. 2002 Jul 15;62(14):4015-22.

30.

Endoglin (CD105) expression in squamous cell carcinoma of the oral cavity.

Schimming R, Marmé D.

Head Neck. 2002 Feb;24(2):151-6.

PMID:
11891945
31.

Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors.

Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G, Marmé D.

Angiogenesis. 2001;4(2):143-54.

PMID:
11806246
32.

Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood.

Reusch P, Barleon B, Weindel K, Martiny-Baron G, Gödde A, Siemeister G, Marmé D.

Angiogenesis. 2001;4(2):123-31.

PMID:
11806244
33.

Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis.

Ballara S, Taylor PC, Reusch P, Marmé D, Feldmann M, Maini RN, Paleolog EM.

Arthritis Rheum. 2001 Sep;44(9):2055-64.

34.

Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy.

Harris AL, Reusch P, Barleon B, Hang C, Dobbs N, Marme D.

Clin Cancer Res. 2001 Jul;7(7):1992-7.

35.

[Tumor angiogenesis: new approaches to cancer therapy].

Marmé D.

Onkologie. 2001 Feb;24 Suppl 1:1-5. German.

PMID:
11441305
36.

Active interaction of human A375 melanoma cells with the lymphatics in vivo.

Papoutsi M, Siemeister G, Weindel K, Tomarev SI, Kurz H, Schächtele C, Martiny-Baron G, Christ B, Marmé D, Wilting J.

Histochem Cell Biol. 2000 Nov;114(5):373-85.

PMID:
11151407
37.

Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.

Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Müller M, Wood J, Martiny-Baron G, Unger C, Marmé D.

Cancer Res. 2000 Sep 1;60(17):4819-24.

38.

Expression of the vascular endothelial growth factor gene is inhibited by p73.

Salimath B, Marmé D, Finkenzeller G.

Oncogene. 2000 Jul 20;19(31):3470-6.

39.

Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases.

Brauers G, Edrada RA, Ebel R, Proksch P, Wray V, Berg A, Gräfe U, Schächtele C, Totzke F, Finkenzeller G, Marme D, Kraus J, Münchbach M, Michel M, Bringmann G, Schaumann K.

J Nat Prod. 2000 Jun;63(6):739-45.

PMID:
10869191
40.

Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro.

Benzinger P, Martiny-Baron G, Reusch P, Siemeister G, Kley JT, Marmé D, Unger C, Massing U.

Biochim Biophys Acta. 2000 Jun 1;1466(1-2):71-8.

41.

Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins.

Stoner M, Wang F, Wormke M, Nguyen T, Samudio I, Vyhlidal C, Marme D, Finkenzeller G, Safe S.

J Biol Chem. 2000 Jul 28;275(30):22769-79.

42.

Induction of the blood-brain barrier marker neurothelin/HT7 in endothelial cells by a variety of tumors in chick embryos.

Papoutsi M, Kurz H, Schächtele C, Marmé D, Christ B, Pröls F, Wilting J.

Histochem Cell Biol. 2000 Feb;113(2):105-13.

PMID:
10766263
43.
44.

Tumorangiogenese: Molekulare Fakten und therapeutische Moglichkeiten.

Marme D.

Chirurg. 1999 Jan;70(1):30-5. German.

PMID:
10068820
45.

Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.

Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marmé D, Gastl G.

Cancer. 1999 Jan 1;85(1):178-87.

PMID:
9921991
46.

The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities.

Siemeister G, Martiny-Baron G, Marmé D.

Cancer Metastasis Rev. 1998 Jun;17(2):241-8. Review. No abstract available.

PMID:
9770121
47.
48.

An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells.

Siemeister G, Schirner M, Reusch P, Barleon B, Marmé D, Martiny-Baron G.

Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4625-9.

49.

Overexpression of PKCepsilon in R6 fibroblasts causes increased production of active TGFbeta.

Cacace AM, Ueffing M, Han EK, Marmè D, Weinstein IB.

J Cell Physiol. 1998 Jun;175(3):314-22.

PMID:
9572476
50.

Supplemental Content

Support Center